However, it is still prudent to use these drugs (bisphosphonates, denosumab, recombinant PTH and romosozumab) with caution, especially in advanced kidney disease, balancing the risk/benefit ratio, since, as documented in this article, pathophysiological pathways are extremely intricate and not completely unraveled yet. The gene discussed is PTH; the disease is kidney disorder.